Trial reportBMC anesthesiology2026
Low-dose esketamine for postoperative fatigue after gynecological laparoscopic surgery: a randomized controlled trial.
Trial report in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostoperative fatigue is a prevalent complication delaying early recovery after gynecological laparoscopic surgery, with no proven effective interventions. To investigate the effect of continuous intraoperative low-dose esketamine on postoperative fatigue in patients undergoing gynecological laparoscopic surgery.
methodsThis single-center, double-blind, randomized placebo-controlled trial enrolled 116 elective gynecological laparoscopic surgery patients, randomly assigned 1:1 to the esketamine group (0.2 mg·kg⁻¹·h⁻¹ esketamine infusion during surgery, n = 58) or control group (equal volume normal saline, n = 58). The primary outcome was the incidence of postoperative fatigue on postoperative day 1 (POD1, Chalder Fatigue Scale score ≥ 4). Secondary outcomes included Chalder Fatigue Scale scores, 15-item Quality of Recovery (QoR-15) scores, Visual Analogue Scale (VAS) pain scores, perioperative drug consumption, and safety events.
resultsIn the primary intention-to-treat analysis, the incidence of POD1 postoperative fatigue was 23.3% (14/60) in the esketamine group and 40.0% (24/60) in the control group (risk difference - 16.7%, OR = 0.46, 95% CI 0.21-1.01, P = 0.050). Esketamine group had significantly lower POD1 fatigue scores, better recovery quality and pain control on POD1 and POD3, reduced intraoperative sufentanil and ephedrine consumption, (all P < 0.05). No significant differences in adverse events were observed between groups (all P > 0.05).
conclusionIntraoperative low-dose esketamine shows a favorable effect on reducing postoperative fatigue, and significantly improves recovery quality and analgesia, without increasing adverse events in patients undergoing gynecological laparoscopic surgery. The primary ITT analysis shows a borderline significant reduction in fatigue incidence, which is supported by a statistically significant result in the per-protocol sensitivity analysis.
trial registrationThis study was prospectively registered at the Chinese Clinical Trial Registry (ChiCTR, https://www.chictr.org.cn/showproj.html?proj=290957 ), with the clinical trial registration number ChiCTR2500112382, and the registration date is November 13, 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.